A prospective study of plasma selenium levels and prostate cancer risk

Journal of the National Cancer Institute

Volumn 96, Issue 9, 2004, Pages 696-703

  Li, Haojie ^a   Stampfer, Meir J ^a,b   Giovannucci, Edward L ^a,b   Morris, J Steven ^c   Willett, Walter C ^a,b   Gaziano, J Michael ^a,d   Ma , Jing ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PROSTATE SPECIFIC ANTIGEN; RETINOL; SELENIUM; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CANCER CLASSIFICATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SELENIUM DEFICIENCY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; BLOOD; DISEASE COURSE; HOSPITALIZATION; IMMUNOLOGY; MIDDLE AGED; PATIENT SELECTION; PHYSICIAN; PROSTATE TUMOR; RISK;

ADULT; AGED; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; CASE-CONTROL STUDIES; CONTROLLED CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT SELECTION; PHYSICIANS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SELENIUM; SEVERITY OF ILLNESS INDEX;

EID: 2442622507     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh125     Document Type: Article

References (31)

1. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000;85:60-8.
2. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001;23:3-13.
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, Gellei B, et al. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20: 680-8.
4. Griffin AC. The chemoprevention role of selenium carcinogenesis. In Arnott MS, Van Eys J, Wang YM, editors. Molecular interrelations of nutrition and cancer. New York (NY): Raven Press; 1982. p. 401-8.
5. Webber MM, Perez-Ripoll EA, James GT. Inhibitory effects of selenium on the growth of DU-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 1985;130:603-9.
6. Redman C, Lee S. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 1998;125:103-10.
7. Redman C, Xu MJ, Peng YM, Scott JA, Payne C, Clark LC, et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis 1997;18:1195-202.
8. Griffin AC. Role of selenium in the chemoprevention of cancer. Adv Cancer Res 1979;29:419-42.
9. Waters DJ, Shen S, Cooley DM, Bostwick DG, Qian J, Combs GF Jr, et al. Effects of dietary selenium supplementation on DNA damage and apoptosis in canine prostate. J Natl Cancer Inst 2003;95:237-41.
10. Shamberger RJ, Willis CE. Selenium distribution and human cancer mortality. CRC Crit Rev Clin Lab Sci 1971;2:211-21.
11. Clark LC, Cantor KP, Allaway WH. Selenium in forage crops and cancer mortality in U.S. counties. Arch Environ Health 1991;46:37-42.
12. Yoshizawa K, Willett WC, Morris JS, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;90:1219-24.
13. van den Brandt PA, Zeegers MP, Bode P, Goldbohm RA. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2003;12:866-71.
14. Nomura AM, Lee J, Stemmermann GN, Combs GF Jr. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2000;9:883-7.
15. Brooks JD, Metter EJ, Chan DW, Sokoll LJ, Landis P, Nelson WG, et al. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol 2001;166:2034-8.
16. Helzlsouer KJ, Huang H, Alberg AJ, Hoffman S, Burke A, Norkus EP, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92:2018-23.
17. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS; Carotene and Retinol Efficacy Trial Co-Investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10:1069-76.
18. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group [published erratum appears in JAMA 1997;277:1520]. JAMA 1996;276:1957-63.
19. Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81: 730-4.
20. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002;11:630-9.
21. Stephenson RA. Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002;29:173-81.
22. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
23. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook N, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996;334:1145-9.
24. Gann PH. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
25. Catalona WJ, Avioli LV. Diagnosis, staging, and surgical treatment of prostatic carcinoma. Arch Intern Med 1987;147:361-3.
26. McKown DM, Morris JS. Rapid measurement of selenium in biological samples using instrumental neutron activation analysis. J Radioanalyt Chem 1978;43:411-20.
27. Gann PH, Hennekens CH, Stampfer MI. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
28. Gann PH, Ma J, Catalona WJ, Stampfer MJ. Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation. J Urol 2002;167:2427-34.
29. Longnecker MP, Stram DO, Taylor PR, Levander OA, Howe M, Veillon C, et al. Use of selenium concentration in whole blood, serum, toenails, or urine as a surrogate measure of selenium intake. Epidemiology 1996;7:384-90.
30. El-Bayoumy K, Richie JP Jr, Boyiri T, Komninou D, Prokopczyk B, Trushin N, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. Cancer Epidemiol Biomarkers Prev 2002;11:1459-65.
31. Klein EA, Lippman SM, Thompson IM, Goodman PJ, Albanes D, Taylor PR, et al. The selenium and vitamin E cancer prevention trial. World J Urol 2003;21:21-7.